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ABSTRACT  
Objective: Comparison of Mitomycin C and BCG in 
treating urinary bladder cancer to devise better agent 
with less complications and good outcomes.  
Materials and Methods: The study was conducted at 
Mayo hospital, Lahore from January 2017 to January 
2018. It included 60 patients suffering from urinary 
bladder tumor. 
Results: The complications such as fever, hematuria and 
dysuria were more associated with BCG; however, it was 
found to be associated with less recurrence rate as 
compared to MMC. 
Conclusion: BCG is more recommended to be used for 
treating urinary bladder cancer as compared to MMC.  
Key Words: bladder cancer, BCG, MMC, 
INTRODUCTION  
Urinary bladder cancer is considered as ninth most 
common cancer in the world. It can be regarded as 
4th most common in United States of America and 
stands 5th in Europe. Its prevalence is increasing 
day by day (Irie et al. 2003). Majority of patients 
arrive clinic with non invasive muscular disease, 
which is superficial in nature. It is a combination of 
tumors with various outcomes (Kassouf & Black 
2017). At early stages, disease is remarked as 
lamina propria (T1) or tiurothelium (Ta). It has 
more prevalence among men as compared to 
women. Initially these tumors are managed by 
cystoscopic observation, which is followed by 
transuretheral resection (TUR) and biopsy 
(Cockerill et al. 2015).  
Mostly the entire tumor is resected; however, two 
third may recur despite complete surgical resection. 
To avoid recurrence, high risk patients are 
administered with adjuvant intravesical therapy 
(Jung et al. 2017). Mitimycin C (MMC) and 
Bacillus Calmete Guerin (BCG) are most common 
agents used for this purpose. Non-muscle invasive 
cancer has high recurrence rate after resection, 
which result in muscle invasive cancer (Zhu et al. 
2013). The use of BCG against cancer was first 
revealed by Centanni and Rezzesi in 1926 A.D. 
Later on, various experiments were conducted to 
apply its use on lung cancer, colon cancer, elanoma 
and leukemia (Friedrich et al. 2007).  
In treatment of superficial bladder cancer, various 
intravesicalcytotoxic agents are used including 
epirubicin, bleomycin, mitomycin C, adriamycin, 
cytosine-arabinoside and thiotepa. The MMC is a 
antitumor antibiotic, which is highly applicable in 
superficial bladder cancer (Verdeja-Robles et al. 
2018). It has recurrence rate of 7 to 81%. However, 
it has negative outcomes such as contact dermatitits 
and chemical cystitis. On the other hand, BCG is 
another agent used under nonspecific 
immunotherapy for bladder cancer from 1976 AD 
(Sutton et al. 2000). The recent development in 
field has suggested that high recurrence risk of 
tumors should be dealt with MMC, BCG, 
doxorubicin or epirubicin. BCG is considered best 
among these agents on basis of recurrence rate. 
However, it is more toxic than MMC. Some studies 
have indicated absurdity about BCG preference 
over MMC (Witjes et al. 2013). Thus, the purpose 
of present study is to compare outcomes of MMC 
and BCG in individuals of urinary bladder tumor. 
This will help patients to adopt better therapy in 
future and prevent recurrence.  
MATERIALS AND METHODS  
This study was conducted at Urology department of 
Mayo hospital. It included 60 patients, and lasted 
from January 2017 to January 2018. History for all 
patients was noted followed by clinical 
examination. Provisional diagnosis included 
ultrasound, plain X-ray abdomen, CT scan 
abdomen and pelvis. After diagnosis stage, 
preparation for cystoscopic biopsy and surgery was 
done. Followed by histopathology, either 
chemotherapy by MMC or immunotherapy by 
BCG was assigned for each patient. The age range 
for patients under study was 18 to 80 years. The 
patients with only Ta and T1 non muscle invasive 
tumor were included in present study, whereas, 
individuals with advanced bladder tumor were 
excluded.  
RESULTS  
Out of 60 patients, 50 (83.33%) were male and 10 
(16.66%) were females. The selected drugs were 
administered on basis of disease stage. The 
individuals with T1, G1 and G2 were given with 
MMC. It was rendered as 40mg in 20ml normal 
saline followed by 6 hours of surgery. On the other 
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hand, 1 vial of BCG was diluted in 50 ml of normal 
saline and administed after 14 hours of surgery. 
The agent was maintained in bladder for about 2 
hours. The drugs were affiliated with various side 
effects. Hematuria was evident in 5% and 3% 
patients administered with MMC and BCG. 
Dysuria was shown by 19% and 9% of MMC and 
BCG patients. Fever was present in 8% and 3% of 
BCG and MMC patients. Cystitis was developed in 
43% and 32% of BCG and MMC patients. 
Recurrence rate was lower for BCG, which was 
only 1%. 
DISCUSSION  
Urinary bladder cancer is most common 
malignancy of urinary tract. It has prevalence of 
19% in women, whereas, it is 6th common cancer in 
men. Majority of patients are diagnosed after the 
age of 60 years. Recurrence is a main issue faced 
by patient and surgeon after TUR. Its recurrence 
rate is estimated to be 80%. BCG and MMC are 
highly recommended for treatment of bladder 
cancer. Previous research works have indicated that 
treatment with BCG is better than that of MMC. 
These findings are similar to the present study. 
Many studies have referred to intensive side effects 
of BCG. Same was shown in present study. 
However, BCG has an advantage of reducing 
recurrence rate of tumor. In present study, cystitis 
after BCG was noted to be 43%. Similar findings 
were indicated by study of Di Stasi et al. However, 
hematuria was found less in present study as 
compared to previous research works. 
Previous work by Correa et al showed recurrence 
rate of 38% affiliated with BCG. However, the 
recurrence rate in present work was found to be 
only 1%. Consequently, numerous studies have 
advocated use of BCG in reducing recurrence rate 
of bladder tumor. Although AUA Guidelines have 
recommended use of both agents, criteria of their 
use is still unclear for treating bladder cancer.  
CONCLUSION  
It can be concluded that use of Bacillus Chalmette 
Gureau (BCG) is more recommended as compared 
to Mitomycin C, on the basis of low recurrence rate 
and hindering progress of cancer. However, MMC 
was affiliated with fewer side effects as compared 
to BCG.  
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